Stuart L. Schreiber

Broad Institute — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

165h-index131.9kcitations1.3kworks5.62yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chemical Synthesis and Analysis(148), Computational Drug Discovery Methods(97), Synthetic Organic Chemistry Methods(97), Signaling Pathways in Disease(96), Melanoma and MAPK Pathways(85)

Publications1.3k total

Author Correction: Diversity-oriented synthesis yields novel multistage antimalarial inhibitors

Nature·2025Open Access

Suppl. Figure S3 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S10 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S9 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl Figure S4 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Table ST1 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S5 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S13 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Table ST4 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S12 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S2 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S6 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S14 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Table ST9 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S15 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Table ST7 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl Figure S11 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S8 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl.Figure S16 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

Suppl. Figure S7 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

2025Open Access

page 1 of 65Next →

Frequent Co-authors

Paul A. Clemons(8), Alykhan F. Shamji(8), Clary B. Clish(6), John K. Eaton(5), Christian A. Hassig(5), Christina M. Grozinger(5), Vlado Dančík(5), Vasanthi S. Viswanathan(4), Jaime H. Cheah(4), B Bernstein(4), John G. Doench(4), Joshua A. Bittker(4), Joanne Kotz(4), Yilong Zou(4), Amy Deik(4), Brent R. Stockwell(3), Stephen J. Haggarty(3), Jesse S. Boehm(3), Brinton Seashore‐Ludlow(3), Matthew G. Rees(3)